The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
分析师的判决：7位专家眼中的蓝图药物
Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
在过去的三个月中，7位分析师对Blueprint Medicines（纳斯达克股票代码：BPMC）进行了分析，揭示了从看涨到看跌的不同观点。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表总结了他们最近的评估，说明了过去30天不断变化的情绪，并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $97.43, along with a high estimate of $125.00 and a low estimate of $65.00. This upward trend is apparent, with the current average reflecting a 73.98% increase from the previous average price target of $56.00.
分析师提供了更深入的见解，确定了12个月的目标股价，平均目标价为97.43美元，最高估计为125.00美元，低估值为65.00美元。这种上升趋势显而易见，当前的平均价格较之前的平均目标价56.00美元上涨了73.98％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
In examining recent...
在研究...
登录免费看全文
登录/注册